Budesonide CIR capsules once or twice daily in active Crohn's disease. A randomized placebo controlled study in the USA

被引：0
|
作者：
Tremaine, WJ
Hanauer, SB
Katz, S
Winston, BD
Levine, JG
Persson, T
Persson, A
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Nassau Gastroenterol Assoc PC, Great Neck, NY USA
[4] N Houston Gastroenterol Clin PA, Houston, TX USA
[5] AstraZeneca US, Wayne, PA USA
[6] AstraZeneca R&D, Lund, Sweden
来源：
GASTROENTEROLOGY | 2001年 / 120卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
4019
引用
收藏
页码：A748 / A748
页数：1
相关论文
共 50 条
  • [1] Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: A randomized placebo-controlled study in the United States
    Tremaine, WJ
    Hanauer, SB
    Katz, S
    Winston, BD
    Levine, JG
    Persson, T
    Persson, A
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (07): : 1748 - 1754
  • [2] Pharmacokinetics of budesonide controlled ileal release capsules in active Crohn's disease.
    Naber, AHJ
    Olaison, G
    Smedh, K
    Jansen, JBMJ
    Sjodahl, R
    GASTROENTEROLOGY, 1996, 110 (04) : A977 - A977
  • [3] Healthcare cost savings with budesonide controlled ileal release capsules (CIR) in Crohn's disease
    Lofberg, R
    Danielsson, A
    Floren, CH
    Borg, S
    Ericsson, K
    GASTROENTEROLOGY, 2001, 120 (05) : A749 - A749
  • [4] Budesonide controlled ileal release (CIR) capsules in prednisolone-dependent patients with Crohn's disease
    Cortot, A
    Colombel, JF
    Rutgeerts, P
    Lauritsen, K
    Malchow, H
    Hamling, J
    Winter, T
    Pallant, D
    Pettersson, E
    GASTROENTEROLOGY, 1999, 116 (04) : A692 - A693
  • [5] Budesonide CIR capsules in children and adults with Crohn's disease: A pharmacokinetic and tolerability study.
    Lindquist, B
    Linander, H
    Nilsson, M
    Persson, T
    GASTROENTEROLOGY, 1999, 116 (04) : A785 - A785
  • [6] Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease
    Lundin, PDP
    Edsbäcker, S
    Bergstrand, M
    Ejderhamn, J
    Linander, H
    Högberg, L
    Persson, T
    Escher, JC
    Lindquist, B
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (01) : 85 - 92
  • [7] Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study
    Lofberg, R
    Rutgeerts, P
    Malchow, H
    Lamers, C
    Danielsson, A
    Olaison, G
    Jewell, D
    Thomsen, OO
    LorenzMeyer, H
    Goebell, H
    Hodgson, H
    Persson, T
    Seidegard, C
    GUT, 1996, 39 (01) : 82 - 86
  • [8] Effect of Esomeprazole 40 mg Once or Twice Daily on Asthma A Randomized, Placebo-controlled Study
    Kiljander, Toni O.
    Junghard, Ola
    Beckman, Ola
    Lind, Tore
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181 (10) : 1042 - 1048
  • [9] Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease
    Lundin, P
    Naber, T
    Nilsson, M
    Edsbäcker, S
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (01) : 45 - 51
  • [10] Budesonide CIR is more effective than mesalazine in active Crohn's disease. A 16 week, international, randomized, double-blind multicentre trial
    Thomsen, OO
    Cortot, A
    Jewell, D
    Wright, JP
    Winter, T
    Veloso, FT
    Vatn, M
    Persson, T
    Pettersson, E
    GUT, 1997, 41 : A70 - A70
12345